entertainment -WSS

entertainment

author：focus 2025-09-27 22:48:58 - browse：58

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Medical student insurance fails on mental health care coverage

hotspot

WSS

Medicare drug price negotiation hearing pits pharma v Biden admin

For AI in health care standards, federal regulators join with industry group

Ukraine and a new approach to mental health in war

Thermo Fisher plant for manufacturing gene therapies to expand

He's 19 months old and has one of the world’s rarest diseases

Second xenotransplant done with gene

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Ozempic has benefits for kidney disease as well as diabetes

Continuity nursing helped my family in our darkest PICU moments

Why are Kaiser Permanente staff considering a strike?

The high cost of giving birth even with insurance

Ukraine and a new approach to mental health in war

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why are Kaiser Permanente staff considering a strike?

Hepatitis C has a cure — but many Americans still lack access to it

Changes to biosimilar regulatory framework must prioritize patients

hotspot

Why Talkspace is targeting Medicare, a tricky market

Experts study whether long Covid risk adds up with each reinfection

Microsoft's Peter Lee: Generative AI could help doctors be more human

Biotech stock slump in 2023: awaiting the turnaround

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

$1 billion proposal to grow Boston, Massachusetts biotech

explore

Wikipedia

hotspot

hotspot